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Abstract  
Objective: Inflammatory mediators have been implicated in the early stages of 
cardiovascular disease development, including hypertension.  Since global reports reflect a 
higher hypertension prevalence in black than white populations, we hypothesise the 
involvement of specific inflammatory mediators. We therefore compared a detailed range of 
22 inflammatory mediators between young black and white adults, and determined the 
relationship with blood pressure. Approach and Results: We included 1197 adults (20-30 
years; 50% black; 52% female) with detailed ambulatory blood pressures. Blood samples 
were analysed for 22 inflammatory mediators. For pro-inflammatory mediators, the black 
adults had higher C-reactive protein, interferon-inducible T-cell alpha chemoattractant, 
macrophage inflammatory protein 3 alpha (all p≤0.008), but lower interferon-gamma, 
interleukin (IL)-1β, IL-8, IL-12, IL-17A, and tumour necrosis factor alpha (all p≤0.048). For 
anti-inflammatory mediators the black group consistently had lower levels (IL-5, IL-10 and IL-
13 (all p≤0.012)), resulting in generally higher pro-to-anti-inflammatory ratios in black than 
white adults (p≤0.001). In mediators with pro- and anti-inflammatory functions, the black 
group had lower granulocyte-macrophage colony-stimulating factor and IL-6 (both p≤0.010). 
These patterns were confirmed after adjustment for age, sex and waist circumference, or 
when stratifying by hypertensive status, sex and socio-economic status. Multi-variable 
adjusted regression analyses and factor analysis yielded no relationship between 
inflammatory mediators and blood pressure in this young healthy population. Conclusions: 
Black and white ethnic groups each consistently presented with unique inflammatory 
mediator patterns regardless of blood pressure, sex or social class. No association with 
blood pressure was seen in either of the groups. 
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Abbreviations 
CVD  Cardiovascular disease 
SBP  Systolic blood pressure 
DBP  Diastolic blood pressure 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
IFN-γ   Interferon gamma 
IL-1 β   Interleukin 1 beta  
IL-2  Interleukin 2  
IL-4  Interleukin 4 
IL-5  Interleukin 5 
IL-6  Interleukin 6 
IL-8  Interleukin 8 
IL-10  Interleukin 10 
IL-12  Interleukin 12 
IL-13  Interleukin 13 
IL-17A  Interleukin 17A 
IL-23  Interleukin 23 
ITAC  Interferon-inducible T-cell alpha chemoattractant  
MIP-1α  Macrophage inflammatory protein 1-alpha 
MIP-1β  Macrophage inflammatory protein 1-beta 
MIP-3α Macrophage inflammatory protein 3-alpha 
TNFα  Tumour Necrosis Factor Alpha  
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Introduction 
Inflammatory mediators have been implicated in the development of chronic diseases,1-3 
including hypertension and cardiovascular disease (CVD).4 However, the physiological 
mechanisms through which this occur, are not all completely understood.5-9 A number of pro-
inflammatory mediators, such as CRP,10 IL-6,10-12 IL-17A,12, 13 and TNF-α12 contribute to an 
increase in blood pressure. In contrast, others such as IL-10, GM-CSF and IFN-γ show 
inverse associations with blood pressure.12, 14 The functions of numerous other pro- and anti-
inflammatory mediators such as IL-21,15 and ITAC16 are not yet clearly known, and neither is 
their association with blood pressure and CVD. Pro- and anti-inflammatory mediators are 
mainly produced by helper T cells and macrophages but also by other cell populations such 
as monocytes and certain nonimmune cells.17 
Globally it has been reported that black populations have higher blood pressure than white 
populations.18, 19 Many mechanisms have been proposed to explain this, such as a 
suppressed renin-angiotensin-aldosterone-system and salt sensitivity in black populations.20-
22 Based on our previous work in South Africa,23, 24 another possible mechanism could be 
related to inflammation. Differences in pro- and anti-inflammatory mediator concentrations 
between ethnic groups have indeed been reported, e.g. in populations of African, European 
and South American descent.24-30 Findings remain contradictory;29 for example Mwantembe 
et al.25 found that IL-1β levels were higher in black than in white adults, whereas Albandar et 
al.27 found levels to be highest in Hispanics, followed by white individuals, while black 
participants exhibited the lowest levels. With regards to IL-6, Hong et al.31 reported no ethnic 
differences between black and white participants, while Elkind et al.26 found black individuals 
to have higher levels than white individuals. In South Africa, it was consistently shown that 
black individuals display higher levels of pro-inflammatory markers than whites.23, 24, 32 
In this study we therefore compared a detailed range of 22 pro- and anti-inflammatory 
mediators and numerous blood pressure measurements between young black and white 
adults. We also investigated the relationships between blood pressure and the pro- and anti-
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inflammatory mediator profile. This unique young disease-free sample allowed us to 
examine ethnic differences without interference from overt cardiovascular disease.  
Methodology 
Study population 
This study forms part of the African Prospective study on the Early Detection and 
Identification of Cardiovascular disease and Hypertension (African-PREDICT).33 We 
recruited young black and white, men and women, between the ages of 20-30 years. 
African-PREDICT included apparently healthy individuals who were HIV uninfected; had a 
screening office brachial blood pressure of <140 mmHg systolic and <90 mmHg diastolic; 
had no self-reported previous diagnosis or used any medication for a chronic disease; and, if 
female, were not currently pregnant or lactating. Although individuals with office brachial BP 
of ≥140 and/or ≥90 were excluded during screening, there was an average two-week period 
between the screening and research phases. Some participants were classified as being 
hypertensive based on 24hr ambulatory blood pressure during the research phase and were 
included in this study. This study analysed data for participants included in the baseline 
phase of the study (n=1202). Participants on anti-inflammatory medication or with missing 
biochemical analyses data were additionally excluded, resulting in a total population size of 
n=1189. The study was approved by the Health Research Ethics Committee (HREC) of the 
North-West University (NWU-00058-18-A1), adheres to the Declaration of Helsinki and all 
participants in the study provided written informed consent prior to participation.  
General Measurements  
Self-reported data with regards to demographic and lifestyle information were collected using 
a questionnaire. Socio-economic status was calculated using a point system that was 
adapted from Kuppuswamy's Socio-economic Status Scale34 for a South African 
environment. Height, weight and waist circumference were measured using standard 
methods.33 Body mass index (BMI) was calculated using weight (kg) / height(m)2. A 
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compact, chest-worn accelerometric device (Actiheart4 CamNtech Ltd and CamNtech Inc, 
UK) was used to objectively measure physical activity over a maximum period of 7 days.  
Blood pressure 
Brachial blood pressure 
Duplicate brachial blood pressure measurements were done on the left and right arms, with 
a 5-minute interval in-between, in a seated and resting state. We used the Dinamap® 
Procare 200 Blood Pressure Monitor (GE Medical Systems, Milwaukee, WI, USA).  
Central blood pressure  
cSBP was shown to provide a better estimate of cardiovascular mortality than other 
measures of blood pressure.35 We therefore performed pulse wave analysis using the 
SphygmoCor XCEL (AtCor Medical, Sydney, Australia) device. This technique records the 
peripheral pressure waveforms and generates a corresponding central waveform.36  
Ambulatory blood pressure 
Participants were fitted with a validated 24-hour brachial ambulatory blood pressure (ABPM) 
monitor (Card(X)plore® CE120, Meditech, Budapest, Hungary). The apparatus was 
programmed to record every 30 minutes during the day (06h00 to 22h00) and every hour 
during the night (22h00 to 06h00).37 Participants had a mean successful recording rate of 
88%. 
Biological sampling and biochemical analyses 
Participants fasted overnight for at least eight hours prior to attending the day of research 
measurements. Blood samples were collected from the median cubital vein. The samples 
were prepared according to standardised protocols and stored at -80°C until the time of 
analysis.  
Serum samples were analysed for high-sensitivity C-reactive protein (CRP), total cholesterol, 
low- and high-density lipoprotein cholesterol, glucose and γ-glutamyltransferase (GGT) 
(Cobas Integra® 400plus, Roche, Basel, Switzerland). Serum creatinine concentrations were 
7 
 
measured using the Creatinine Jaffé Gen.2 reagent (Roche, Basel, Switzerland). Estimated 
glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology (CKD-EPI) formula, without race in the equation as this is not appropriate for a 
South African population.38, 39 Serum cotinine was analysed using a chemiluminescence 
method on the Immulite (Siemens, Erlangen, Germany) apparatus. EDTA whole blood 
samples were analysed for white blood cell, neutrophil, basophil, eosinophil, lymphocyte and 
monocyte count (Coulter AcT5 diff OV Hematology analyzer, Beckman Coulter, Brea, CA, 
US). 
A MILLIPEX Map Human High Sensitivity T Cell Magnetic Bead Panel (EMD Millipore, 
Merck, Missouri, USA) was used to analyse 21 cytokines. This multiplex panel was analysed 
using Luminex xMAP technology on the Luminex 200TM analyser. This technology performed 
immunoassays on the surface of fluorescent-coded magnetic beads known as MagPlex-C 
microspheres. Microspheres were colour-coded with two fluorescent dyes. Through precise 
concentrations of these dyes, distinctly coloured bead sets of 500 5.6 μm polystyrene 
microspheres or 80 6.45 μm magnetic microspheres were created, each of which was 
coated with a specific capture antibody. A biotinylated detection antibody was introduced, 
and the mixture was then incubated in a streptavidin-phycoerythrin (PE) conjugate reporter. 
The fluorescent intensity of the reporter was determined which correlates with the 
concentration of a given analyte in solution. A standard curve was generated to calculate 
final analyte concentration. 
Statistical analyses 
IBM®, SPSS® version 24 (IBM Corporation, Armonk, New York) was used for data analysis. 
GraphPad Prism 5.03 (GraphPad Software, San Diego) was used all for graphics. 
Continuous variables were inspected for normality using QQ plots as well as inspection of 
skewness and kurtosis. Variables with non-Gaussian distributions were logarithmically 
transformed. To evaluate if data should be presented and analysed independently by sex or 
ethnicity, we investigated the interactions of these variables on the relationship between 
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cSBP, 24hr systolic blood pressure (SBP) and the full range of pro- and anti-inflammatory 
mediators. We divided our groups by ethnicity based on the interactions found (Table S1). 
Pro- to anti-inflammatory ratios were calculated based on literature,40, 41 and new ratios were 
suggested based on instances where pro-inflammatory mediators were higher and anti-
inflammatory mediators were lower in the black and white groups. T-tests and Chi-square 
tests were used to compare the profiles of black and white participants. Analyses of 
covariance, adjusting for age; sex; and waist circumference, were used for ethnic 
comparisons of pro- and anti-inflammatory mediator concentrations. This was also done in 
normotensive and hypertensive groups, and groups categorised according to socio-
economic status. The relationships between measures of blood pressure as the dependent 
variables and pro- and anti-inflammatory mediators as the main independent variables were 
explored using Pearson, partial and multiple regression analyses. Factor analyses were 
performed using the factor function of SPSS. Principal component analyses were used and 
factors with an eigenvalue >1 were retained. Varimax rotation was used to obtain 
independent interpretable factors. A factor loading of ≥0.3 was used to interpret the factor 
patterns. Double loading was handled by placing the variable in the factor with the strongest 
loading factor. Factor scores with a cumulative percentage of >50 were subsequently used 
for multiple regression analyses to determine the relationship between measures of blood 
pressure and factor scores.  
Results 
The general characteristics of the participants (n=1202) are shown in Table 1. The overall 
mean blood pressures of all participants were in the optimal blood pressure ranges.37 
Compared to the white group, black individuals had lower 24hr and night SBP readings (all 
p≤0.027), but higher office diastolic blood pressure (DBP) (p<0.001) and central SBP 
(p<0.001). With regards to body composition, the black group had a lower BMI and waist 
circumference.  
9 
 
Black participants showed higher levels of the pro-inflammatory mediators CRP, ITAC, 
MIP3-α (all p≤0.008), but lower levels of IFN-γ, IL-1β, IL-8, IL-12, IL-17A, and TNF-α (all 
p≤0.048). Regarding anti-inflammatory mediators, black individuals had lower levels of IL-5, 
IL-10 and IL-13 (all p≤0.012). In terms of mediators that display both pro- and anti-
inflammatory functions, we observed lower levels of both GM-CSF and IL-6 (all p≤0.010) in 
the black group. Black participants generally had higher pro-to-anti-inflammatory ratios than 
their white counterparts (p≤0.001). The black group exhibited lower white blood cell, 
neutrophil, monocyte, eosinophil and basophil counts (all p0.013).  
We also performed analyses of covariance comparing black and white individuals (Table 2), 
adjusting for age, sex and waist circumference. Findings were largely similar (Figure 1).   
Additionally, we compared ethnic groups, stratified by hypertensive status, sex and the 
middle socio-economic status group to account for the role these factors may play in 
determining inflammatory mediator status (Table II-VI). Similar to the ethnic comparisons in 
the total group, nearly identical ethnic profiles were seen, independent of hypertension 
status, sex and socio-economic status. Figure 1 summarises the pro- and anti-inflammatory 
mediator profiles of black and white groups based on Table 3 and Tables I-VI. 
Multiple regression analyses were performed to determine whether blood pressure (24hr 
SBP, 24hr DBP, cSBP and nighttime SBP) is related to pro- and anti-inflammatory mediator 
concentrations within each ethnic group. In our young, healthy populations, the multiple 
regression analyses yielded no consistent statistically significant results (Figures 2-3 and 
Figures I-II).  
Factor analyses were performed with the pro- and anti-inflammatory mediator data to 
determine factor scores (Table VII-IX). Factor scores were subsequently used for multiple 
regressions analyses to determine whether blood pressure (24hr SBP, 24hr DBP, cSBP and 
nighttime SBP) is related to the pro- and anti-inflammatory mediator factors; this yielded no 
statistically significant results (Table X). 
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Table 1. Characteristics of young black and white adults. 
 Black (n=599) White (n=590) P 
Age, years 24.5± 3.17 24.6 ± 3.06 0.55 
Male, n (%) 296 (49.0) 281 (47.4) 0.58 
Socio-economic Status    
       Low, n (%) 356 (58.9) 118 (19.9) <0.001 
       Middle, n (%) 163 (27.0) 182 (30.7)  
       High, n (%) 85 (14.1) 293 (49.4)  
Office BP (mmHg)    
     Brachial SBP 117 ± 12.0 116 ± 12.6  0.16 
     Brachial DBP 79.4 ± 8.37 77.7 ± 8.12 <0.001 
     Central SBP 110 ± 9.58 105 ± 9.69 <0.001 
Ambulatory BP (mmHg)    
     24h SBP 116 ± 8.99 118 ± 9.82 <0.001 
     24h DBP 68.8 ± 5.93 68.5 ± 5.86 0.45 
     Night SBP 107 ± 10.1 109 ± 10.9 0.027 
     Night DBP 59.6 ± 6.77 59.1 ± 6.70 0.14 
     Hypertensive status, n (%) 50 (8.40) 78 (13.2) 0.009 
Body Composition    
     Body mass index (kg/m2) 24.0 (17.6; 35.3) 25.0 (18.8; 35.1) <0.001 
     Waist circumference (cm) 77.0 (63.0; 97.0) 81.5 (64.9; 107) <0.001 
        Male 75.9 (64.3; 92.3) 88.5 (74.0; 110) 0.007 
        Female 78.2 (62.0; 102) 75.7 (63.5; 99.5) <0.001 
Inflammatory Markers    
Pro-Inflammatory    
     CRP (mg/L) 1.01 (0.09; 11.1) 0.78 (0.08; 7.89) 0.002 
     Fractalkine (pg/mL) 28.0 (9.02; 71.7) 29.3 (9.82; 74.3) 0.24 
     IFN-γ (pg/mL) 6.75 (1.65; 21.5) 7.82 (163; 22.0) 0.002 
     IL-1β (pg/mL) 0.98 (0.20; 3.74) 1.08 (0.27; 3.66) 0.033 
     IL-2 (pg/mL) 0.78 (0.13; 4.11) 0.85 (0.16; 3.91) 0.21 
     IL-7 (pg/mL) 5.63 (1.34; 18.7) 5.65 (1.12; 18.8) 0.95 
     IL-8 (pg/mL) 1.74 (0.45; 5.97) 1.91 (0.47; 7.88) 0.048 
     IL-12 (pg/mL) 1.75 (0.35; 6.40) 1.97 (0.45; 6.72) 0.024 
     IL-17 A (pg/mL) 3.19 (0.64; 13.5) 3.57 (0.67; 14.1) 0.044 
     IL-23 (pg/mL) 119 (13.4; 600) 133 (12.9; 668) 0.10 
     ITAC (pg/mL) 4.70 (1.45; 19.9) 3.67 (1.40; 11.6) <0.001 
     MIP-1α (pg/mL) 9.57 (2.74; 26.3) 10.3 (2.85; 27.0) 0.089 
     MIP-1β (pg/mL) 7.06 (2.70; 15.6) 7.28 (2.88; 16.4) 0.33 
     MIP-3α (pg/mL) 2.17 (0.54; 8.12) 1.90 (0.48; 6.61) 0.008 
     TNF-α (pg/mL) 1.61 (0.41; 5.29) 1.79 (0.49; 5.73) 0.016 
Anti-Inflammatory    
     IL-4 (pg/mL) 42.62 (7.33; 155) 43.85 (7.92; 154) 0.61 
     IL-5 (pg/mL) 0.89 (0.20; 3.88) 1.02 (0.26; 3.99) 0.012 
     IL-10 (pg/mL) 4.38 (0.89; 21.1) 5.42 (1.14; 21.2) <0.001 
     IL-13 (pg/mL) 3.88 (0.58; 23.2) 5.04 (0.69; 30.3) <0.001 
Pro- and Anti-Inflammatory      
     IL-6 (pg/mL) 1.81 (0.25; 9.84) 2.35 (0.30; 12.8) <0.001 
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     IL-21 (pg/mL) 1.34 (0.21; 5.53) 1.49 (0.26; 6.53) 0.074 
     GM-CSF (pg/mL)  7.23 (1.22; 32.5) 8.47 (1.22; 38.1) 0.010 
Pro-to-Anti Inflammatory Ratios     
     IL-6 to IL-10 0.41 (0.10; 2.03) 0.43 (0.12; 2.02) 0.39 
     IL-1β to IL-10 0.22 (0.07;0.73) 0.19 (0.07; 0.52) 0.001 
     TNF-α to IL-10 0.37 (0.17; 0.98) 0.33 (0.15; 1.01) <0.001 
     CRP to IL-10 0.23 (0.01; 3.80) 0.14 (0.01; 2.40) <0.001 
     MIP-1α to IL-10 2.13 (0.71; 7.72) 1.82 (0.59; 5.76) <0.001 
     ITAC to IL-4 0.11 (0.02; 0.90) 0.08 (0.02; 0.67) <0.001 
     ITAC to IL- 5 5.33 (1.10; 32.5) 3.60 (0.79; 17.7) <0.001 
     ITAC to IL-10 1.08 (0.27; 6.65) 0.68 (0.21; 3.12) <0.001 
     ITAC to IL-13 1.22 (0.17; 9.92) 0.73 (0.10; 5.66) <0.001 
Biochemical Markers and White Blood Cell Counts 
     Total Cholesterol (mmol/L) 3.47 ± 0.97 4.04 ± 1.33  <0.001 
     HDL-C (mmol/L) 1.14 ± 0.38 1.17 ± 0.46 0.28 
     LDL-C (mmol/L) 2.07 (0.99; 3.71) 2.45 (1.20; 4.42) <0.001 
     Triglycerides (mmol/L) 0.64 (0.31; 1.37) 0.80 (0.33; 2.11) <0.001 
     Glucose (mmol/L) 3.94 ± 1.03 4.25 ± 1.09 <0.001 
     eGFR (ml/min/1.73m2) 118 ± 14.5 106 ± 16.1 <0.001 
     White blood cell counts (x109/L) 5.21 (3.10; 8.40) 5.79 (3.80; 9.36) <0.001 
     Neutrophils (x109/L) 2.43 (1.03; 5.49) 2.93 (1.35; 5.95) <0.001 
     Lymphocytes (x109/L) 2.02 (1.26; 3.24) 1.98 (1.29; 3.01) 0.26 
     Monocytes (x109/L) 0.30 (0.14; 0.57) 0.42 (0.20; 0.79) <0.001 
     Eosinophils (x109/L) 0.14 (0.05; 0.41) 0.15 (0.06; 0.39) 0.008 
     Basophils (x109/L) 0.04 (0.01; 0.11) 0.04 (0.02; 0.10) 0.013 
Health Behaviours    
     Serum cotinine (ng/ml) 4.04 (1.00; 341) 3.22 (1.00; 308) 0.081 
     Self-Reported Tobacco use n (%) 154 (25.5) 132 (22.3) 0.18 
     -glutamyltransferase (U/L) 22.2 (8.40; 66.2) 14.8 (5.40; 46.6) <0.001 
     Self-Reported Alcohol use, n (%) 333 (55.8) 330 (55.7) 0.99 
     Hormonal Contraceptive Use,  
     n (% of women) 
143 (47.2) 130 (41.9) 0.19 
Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressure; BMI, Body mass index; 
HDL-C High density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol. Bold values 
indicate P<0.05. Data presented as mean ± SD; or geometric mean 95 C.I. Granulocyte-macrophage 
colony-stimulating factor (GM-CSF), Interferon gamma (IFN-γ), Interleukin 1 beta (IL-1β), Interleukin 2 (IL-2), 
Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 10 
(IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 17A (IL-17A), Interleukin 21 (IL-21), Interleukin 
23  (IL-23), Interferon-inducible T-cell alpha chemoattractant (ITAC), Macrophage inflammatory protein 1-alpha 
(MIP-1α), Macrophage inflammatory protein 1-beta (MIP-1β), Macrophage inflammatory protein 3-alpha (MIP-
3α) and Tumour Necrosis Factor Alpha (TNFα). 
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Table 2. A comparison of cytokine concentrations between black and white individuals, 
adjusted for age, sex and waist circumference. 
 Black (n=599) White (n=590) p Difference: 
Black 
minus 
White 
Inflammatory Markers     
Pro-Inflammatory     
     CRP (mg/L) 1.16 (1.05; 1.29) 0.67 (0.61; 0.75) <0.001 0.49 
     Fractalkine (pg/mL) 27.9 (26.4; 29.3) 29.5 (28.1; 31.1) 0.12 -1.60 
     IFN-γ (pg/mL) 6.68 (6.25; 7.14) 7.93 (7.40; 8.47) 0.001 -1.25 
     IL-1β (pg/mL) 0.97 (0.91; 1.04) 1.09 (1.02; 1.17) 0.021 -0.12 
     IL-2 (pg/mL) 0.77 (0.71; 0.85) 0.86 (0.78; 0.93) 0.12 -0.09 
     IL-7 (pg/mL) 5.62 (5.25; 6.01) 5.66 (5.28; 6.07) 0.86 -0.04 
     IL-8 (pg/mL) 1.72 (1.61; 1.84) 1.93 (1.81; 2.07) 0.015 -0.21 
     IL-12 (pg/mL) 1.74 (1.62; 1.87) 1.98 (1.85; 2.13) 0.013 -0.24 
     IL-17 A (pg/mL) 3.16 (2.92; 3.40) 3.61 (3.34; 3.90) 0.016 -0.45 
     IL-23 (pg/mL) 118 (107; 130) 135 (122; 149) 0.059 -17.0 
     ITAC (pg/mL) 4.70 (4.42; 5.00) 3.67 (3.45; 3.90) <0.001 1.03 
     MIP-1α (pg/mL) 9.51 (8.95; 10.1) 10.4 (9.75; 11.0) 0.051 -0.89 
     MIP-1β (pg/mL) 7.24 (6.71; 7.35) 7.31 (7.00; 7.66) 0.20 -0.07 
     MIP-3α (pg/mL) 2.15 (2.01; 2.31) 1.91 (1.79; 2.06) 0.022 0.24 
     TNF-α (pg/mL) 1.59 (1.50; 1.70) 1.80 (1.69; 1.92) 0.008 -0.21 
Anti-Inflammatory     
     IL-4 (pg/mL) 42.5 (39.4; 45.9) 44.2 (40.1; 47.8) 0.49 -1.70 
     IL-5 (pg/mL) 0.88 (0.82; 0.95) 1.03 (0.96; 1.11) 0.004 -0.15 
     IL-10 (pg/mL) 4.32 (4.00; 4.66) 5.48 (5.08; 5.92) <0.001 -1.16 
     IL-13 (pg/mL) 3.83 (3.48; 4.20) 5.11 (4.65; 5.61) <0.001 -1.28 
Pro- and Anti-Inflammatory     
     IL-6 (pg/mL) 1.79 (1.63; 1.96) 2.38 (2.17; 2.62) <0.001 -1.37 
     IL-21 (pg/mL) 1.32 (1.21; 1.43) 1.51 (1.39; 1.64) 0.024 -0.59 
     GM-CSF (pg/mL)  7.18 (6.58; 7.82) 8.55 (7.83; 9.33) 0.006 -0.19 
Pro-to-Anti Inflammatory Ratios    
     IL-6 to IL-10 0.41 (0.38; 0.45) 0.43 (0.40;0.47) 0.38 -0.02 
     IL-1β to IL-10 0.22 (0.21; 0.23) 0.19 (0.18; 0.20) 0.001 0.03 
     TNF-α to IL-10 0.37 (0.36; 0.39) 0.33 (0.32; 0.35) <0.001 0.04 
     CRP to IL-10 0.27 (0.24; 0.31) 0.12 (0.11; 0.14) <0.001 0.15 
     MIP-1α to IL-10 2.14 (2.01; 2.29) 1.81 (1.70; 1.93) <0.001 0.33 
     ITAC to IL-4 0.11 (0.10; 0.12) 0.08 (0.08; 0.09) <0.001 0.03 
     ITAC to IL- 5 5.38 (4.98; 5.82) 3.57 (3.30; 3.86) <0.001 1.81 
     ITAC to IL-10 1.10 (1.02; 1.18) 0.67 (0.62; 0.72) <0.001 0.43 
     ITAC to IL-13 1.24 (1.12; 1.36) 0.77 (0.65; 0.79) <0.001 0.47 
Bold values indicate P<0.05. 
Normotensive status determined using 24-hour ambulatory blood pressure. 
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 Total  NT  HT  M  F  Mid 
SES      
 B W  B W  B W  B W  B W  B W 
Black, n                               599  536  50  307  307  162 
White, n                              590  507  78  311  311  180 
Pro-Inflammatory                  
     CRP (mg/L)                  
     Fractalkine (pg/mL)                  
     IFN-γ (pg/mL)                  
     IL-1β (pg/mL)                  
     IL-2 (pg/mL)                  
     IL-7 (pg/mL)                  
     IL-8 (pg/mL)                  
     IL-12 (pg/mL)                  
     IL-17 A (pg/mL)                  
     IL-23 (pg/mL)                  
     ITAC (pg/mL)                  
     MIP-1α (pg/mL)                  
     MIP-1β (pg/mL)                  
     MIP-3α (pg/mL)                  
     TNF-α (pg/mL)                  
Anti-Inflammatory                  
     IL-4 (pg/mL)                  
     IL-5 (pg/mL)                  
     IL-10 (pg/mL)                  
     IL-13 (pg/mL)                  
Pro- and Anti-
Inflammatory 
                 
     IL-6 (pg/mL)                  
     IL-21 (pg/mL)                  
     GM-CSF (pg/mL)                   
Pro-to-Anti 
Inflammatory Ratios 
                 
     IL-6 to IL-10                  
     IL-1β to IL-10                  
     TNF-α toIL-10                  
     CRP to IL-10                  
     MIP-1α to IL-10                  
     ITAC to IL-4                  
     ITAC to IL- 5                  
     ITAC to IL-10                  
     ITAC to IL-13                  
Figure 1. Comparison of cytokines between black and white individuals.  
Cytokine concentrations that differ between black and white participants are indicated in colour (P<0.05). A 
darker shade indicates a higher value. Adjusted for: age, sex, waist circumference. Based on Tables 3 and II-
VI. Black (B), White (W), Men (M), Women (F), Normotensive (NT), Hypertensive (HT), Middle Socio-
economic Status (Mid SES) 
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Figure 2. Multiple regression analyses showing the relationship between cytokine 
concentrations and 24-hour Systolic Blood Pressure in black and white adults, respectively.  
Adjusted for: sex, socio-economic status, waist circumference, total cholesterol, glucose, gamma 
glutamyltransferase, cotinine, estimated glomerular filtration rate, activity energy expenditure. 
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Figure 3. Multiple regression analyses showing the relationship between cytokine 
concentrations and central systolic blood pressure in black and white adults, respectively. 
Adjusted for: sex, socio-economic status, waist circumference, total cholesterol, glucose, gamma 
glutamyltransferase, cotinine, estimated glomerular filtration rate, activity energy expenditure. 
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Discussion 
Here we report distinct pro- and anti-inflammatory mediator patterns in young and healthy 
white and black adults, independent of sex, hypertension or socio-economic status. Black 
individuals consistently showed higher pro-to-anti-inflammatory ratios when compared to 
their white counterparts. This suggests that the pro- and anti-inflammatory mediator profiles 
in this young healthy cohort are likely to be ethnic-specific and independent of blood 
pressure, sex or socio-economic status. With respect to blood pressure profiles, we found no 
independent relationships between individual inflammatory mediators or inflammatory 
mediator patterns with blood pressure in either of the young ethnic groups. 
Ethnic Profiling  
When examining the pro-to-anti-inflammatory mediator ratios, black adults consistently 
displayed higher ratios, even though they were leaner, had better lipid and glycaemic 
profiles, as well as lower immune cell counts. These results for mediator ratios were found, 
despite the black group having lower levels for six of the fifteen pro-inflammatory mediators 
compared to whites, and higher levels of only three of the fifteen mediators. It is the anti-
inflammatory mediators where the black group displayed lower levels for three of the four 
mediators, which resulted in overall higher pro-to-anti-inflammatory ratios. 
Literature regarding ethnic differences in cytokine concentrations remains inconsistent. 
Elkand et al.26 and Schutte et al.23,24 found CRP levels to be higher in black than in white 
populations, which is in line with our findings. However, Ford et al.42 found no difference in 
CRP levels between African-American and white children and young adults.  
Many studies and systematic reviews focussed on only a few inflammatory mediators at a 
time, and usually the same mediators, such as CRP, IL-6, TNF-α and IL-1β.23, 24, 29, 43-46 This 
simplifies comparison between studies. In our study, we made use of a large range of 
mediators which, while complex, provides a better overall inflammatory profile.  
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One possible explanation for the ethnic-specific mediator profiles may be the differences in 
gene polymorphisms distribution across different ethnic groups.47 It has been shown that 
differences in the inheritance of IL‐6 and IL‐10 genotypes in black populations result in 
higher expression when compared to white populations.47 Differences in genotypes between 
black and white populations have also been seen where IL-2 is concerned.48  
Fifty-nine percent of the black population (versus 20% in whites) falls within a low socio-
economic category. It has recently been shown that childhood environment may play a role 
in the development of inflammatory phenotypes suggesting that the overall low socio-
economic status of this black population may play a role.49 
The effect of potential confounders on the difference in mediator concentrations should be 
taken into consideration. In our comparisons (Figure 1) we adjusted for age, sex and 
abdominal obesity. Yet tobacco use,50 alcohol consumption,51 and obesity,52 which are often 
linked to socio-economic status,53-55 may play a role in increasing pro-inflammatory mediator 
levels, as studies have found that those with a low socio-economic status show elevated 
systemic inflammation.56, 57 However, when counteracting this by comparing black and white 
groups with similar mid-level socio-economic status, the original profiles remained robust, 
suggesting heritability.  
Relationship with blood pressure 
Our motivation for this ethnic comparative study was to identify the involvement of specific 
inflammatory mediators as a possible explanation for the high prevalence of hypertension in 
black populations.58 Our analyses yielded no clear findings, with no individual mediator or 
pattern associating with a range of clinic, central and ambulatory blood pressure measures. 
Since at this early stage in life there are multiple factors that may dominate physiological 
variances in blood pressure – such as differences in renin-angiotensin-aldosterone profiles,58 
arterial stiffness,59 and physical activity60 – blood pressure may not be a measure sensitive 
enough to show small scale, early inflammatory changes in young otherwise healthy 
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individuals. It may thus be useful to focus on more sensitive markers of early cardiovascular 
changes such as arterial stiffness, the microvasculature,61 and endothelial function.62  
In addition to the relationship seen with blood pressure, inflammatory mediators are also 
associated with other disease states. It has been shown that IL-1β, IL-6, IL-17A and TNF-α 
are implicated in the development of atherosclerosis,63, 64 while IL-10 is inversely 
associated.65 More research is required regarding detailed inflammatory mediators in the 
development of CVD in black and white populations. 
Our study results should be interpreted within the framework of its strengths and limitations. 
Participants were screened prior to participation using strict exclusion criteria for conditions 
that may affect the results. The absence of pre-existing chronic diseases afforded us the 
opportunity to investigate the underlying physiology in adults without influence from 
pathology. A further strength of our study is the inclusion of a wide range of pro- and anti-
inflammatory mediators as well as our large sample size. Mediator concentrations were 
established using a high-sensitivity kit which allowed for detection even at low levels. In 
terms of limitations, the black group had a greater proportion of individuals with low socio-
economic status, allowing for potential socio-economic bias. However, sensitivity analyses 
were performed to address this and yielded no changes in our main results. Additionally, this 
study uses cross-sectional data.  
In conclusion, the black and white ethnic groups each consistently presented with unique 
inflammatory mediator patterns regardless of blood pressure, sex or socio-economic status. 
Despite a higher pro-to-anti-inflammatory status of the young black adults, there was no 
association with blood pressure in the black or white groups. Whether these ethnic specific 
patterns will relate to future disease development, needs to be established. 
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